These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 14603552

  • 1. Polycythemia vera: a review.
    Golden C.
    Clin J Oncol Nurs; 2003; 7(5):553-6. PubMed ID: 14603552
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR.
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis and therapy of polycythemia vera.
    Lengfelder E, Merx K, Hehlmann R.
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [Abstract] [Full Text] [Related]

  • 4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 5. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J, Román Barbero A, Nevado Reviriego I.
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract] [Full Text] [Related]

  • 6. Neurologic complications of polycythemia and their impact on therapy.
    Newton LK.
    Oncology (Williston Park); 1990 Mar; 4(3):59-64; discussion 64-6. PubMed ID: 2144446
    [Abstract] [Full Text] [Related]

  • 7. Polycythemia vera.
    Stuart BJ, Viera AJ.
    Am Fam Physician; 2004 May 01; 69(9):2139-44. PubMed ID: 15152961
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular events and intensity of treatment in polycythemia vera.
    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, CYTO-PV Collaborative Group.
    N Engl J Med; 2013 Jan 03; 368(1):22-33. PubMed ID: 23216616
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of arterial compliance in polycythemia vera patients: short and long-term influence of phlebotomy.
    Nemets A, Isakov I, Huerta M, Barshai Y, Oren S, Lugassy G.
    Isr Med Assoc J; 2006 Dec 03; 8(12):845-7. PubMed ID: 17214101
    [Abstract] [Full Text] [Related]

  • 10. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G.
    Semin Thromb Hemost; 2006 Apr 03; 32(3):276-82. PubMed ID: 16673282
    [Abstract] [Full Text] [Related]

  • 11. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr 03; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 12. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, García F, Burgaleta C, Besses C, Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas.
    Haematologica; 2017 Jan 03; 102(1):103-109. PubMed ID: 27686377
    [Abstract] [Full Text] [Related]

  • 13. A contemporary approach to the diagnosis and management of polycythemia vera.
    Tefferi A.
    Curr Hematol Rep; 2003 May 03; 2(3):237-41. PubMed ID: 12901345
    [Abstract] [Full Text] [Related]

  • 14. Polycythemia vera: diagnosis, treatment, and relationship to leukemia.
    Walsh JR.
    Geriatrics; 1978 May 03; 33(5):61-3, 66-9. PubMed ID: 640388
    [No Abstract] [Full Text] [Related]

  • 15. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, GIMEMA CMD-Working Party.
    Haematologica; 2008 Mar 03; 93(3):372-80. PubMed ID: 18268279
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D, Tefferi A.
    Curr Hematol Malig Rep; 2006 Jun 03; 1(2):69-74. PubMed ID: 20425334
    [Abstract] [Full Text] [Related]

  • 17. Survival in a patient with polycythaemia vera for over thirty years: implications for treatment decisions in younger patients.
    Samuelsson J.
    Leuk Lymphoma; 1998 Dec 03; 32(1-2):195-8. PubMed ID: 10037017
    [Abstract] [Full Text] [Related]

  • 18. Polycythemia rubra vera.
    Bilgrami S, Greenberg BR.
    Semin Oncol; 1995 Aug 03; 22(4):307-26. PubMed ID: 7638629
    [Abstract] [Full Text] [Related]

  • 19. Hyperviscosity in polycythemia vera and other red cell abnormalities.
    Kwaan HC, Wang J.
    Semin Thromb Hemost; 2003 Oct 03; 29(5):451-8. PubMed ID: 14631544
    [Abstract] [Full Text] [Related]

  • 20. Polycythemia vera.
    Knoop T.
    Semin Oncol Nurs; 1996 Feb 03; 12(1):70-7. PubMed ID: 8650444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.